2025年9月22日，星宸科技股份有限公司第二届董事会薪酬与考核委员会审议通过向2025年限制性股票 激励计划首次授予激励对象授予限制性股票的议案。薪酬与考核委员会经核实，首次授予的207名激励 对象具备任职资格，符合激励对象条件，不存在不得成为激励对象的情形，激励对象为公司核心技术 （业务）人员，不包括独立董事等。董事会确定的授予日合规，授予条件已成就。薪酬与考核委员会同 意以9月22日为授予日，向激励对象授予92.72万股限制性股票，授予价格33.25元/股。 ...

Core Viewpoint - He Eye Hospital (301103) has disclosed a draft for its 2025 restricted stock incentive plan, aiming to grant a total of 6.37 million shares, with an initial grant of 5.1 million shares at a price of 13 yuan per share [1] Summary by Categories Incentive Plan Details - The company plans to grant restricted stock to no more than 240 individuals as part of the incentive plan [1] - The effective period of the incentive plan will last from the date of stock grant until all granted shares are vested or become invalid, with a maximum duration of 60 months [1]

智通财经APP讯，何氏眼科(301103.SZ)披露2025年限制性股票激励计划(草案)，公司拟向激励对象授予 的限制性股票数量为637万股(其中首次拟授予总量510万股)，本激励计划首次授予的激励对象人数不超 过240人。本激励计划首次授予的限制性股票的授予价格为13元/股。本激励计划的有效期为自限制性股 票授予之日起至激励对象获授的限制性股票全部归属或作废失效之日止，最长不超过60个月。 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002951 证券简称：金时科技 公告编号：2025-066 二、董事会会议审议情况 四川金时科技股份有限公司 （一）审议通过《关于〈四川金时科技股份有限公司2025年限制性股票激励计划（草案）〉及其摘要的 议案》 第三届董事会第十八次会议决议公告 同意公司实行限制性股票激励计划，本次限制性股票激励计划，符合当前公司所处环境变化及未来发展 需要，有利于进一步建立、健全公司长效激励机制，吸引和留住优秀人才，充分调动公司核心技术及业 务人员的积极性，提升公司的核心竞争力，有效地将股东利益、公司利益和核心团队个人利益结合在一 起，确保公司发展战略目标与企业愿景的实现，实现股东利益的最大化，不会对公司生产经营产生不利 影响，不存在损害全体股东尤其是中小股东利益的情形。 本公司及董事会全体成员保证信息披露内容的真实、准确、完整、没有虚假记载、误导性陈述或重大遗 漏。 一、董事会会议召开情况 四川金时科技股份有限公司（以下简称"公司"）第三届董事会第十八次会议于2025年9月19日在公司会 议室以现场结合通讯的方式召开。本次会议通知及会议材料已于2025年9月1 ...

Core Viewpoint - The company has completed the registration of the first grant of the 2025 restricted stock incentive plan, involving 2,188,000 shares, which accounts for 1.56% of the total share capital prior to the grant [2][4][15]. Group 1: Incentive Plan Details - The first grant of restricted stock involves 2,188,000 shares, allocated to 198 incentive recipients [2][5]. - The grant date for the restricted stock is set for September 8, 2025, with the listing date on September 24, 2025 [5][12]. - The restricted stock is sourced from the company's directed issuance of A-share common stock to the incentive recipients [5][8]. Group 2: Approval Process - The approval process for the incentive plan included multiple meetings of the board and supervisory committee, culminating in a shareholder meeting on September 3, 2025, which approved the plan [3][4][12]. - Adjustments were made to the number of recipients and shares granted, reducing the initial plan from 209 recipients and 2,293,000 shares to 198 recipients and 2,188,000 shares [4][11]. Group 3: Performance Conditions - The release of the restricted stock is contingent upon meeting specific performance targets over the 2025-2027 fiscal years, with annual assessments [7][9]. - The performance metrics include revenue growth rate and net profit growth rate, which will determine the percentage of shares that can be released from restrictions [9][10]. Group 4: Financial Implications - The estimated cost of the incentive plan over four years is projected to be 53.5841 million yuan, impacting the company's net profit during the effective period [16][17]. - The funds raised from the incentive plan will be used to supplement the company's working capital [16]. Group 5: Shareholder Impact - Following the completion of the restricted stock grant, the total share capital will increase from 140,446,000 shares to 142,634,000 shares, slightly reducing the controlling shareholder's ownership percentage from 41.44% to 40.80% [14][15].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002657 证券简称：中科金财 公告编号：2025-051 北京中科金财科技股份有限公司 关于2025年限制性股票激励计划首次授予登记完成的公告 首次授予登记人数：12人 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 重要内容提示： 首次授予登记数量：1,303,180股 授予价格：14.60元/股 股票来源：公司回购股份专用证券账户已回购的中科金财A股普通股股票 授予完成日期：2025年9月19日 根据《上市公司股权激励管理办法》（以下简称"《管理办法》 "）、深圳证券交易所、中国证券登记 结算有限责任公司深圳分公司有关规则的规定，北京中科金财科技股份有限公司（以下简称"公司"）完 成了2025年限制性股票激励计划（以下简称"本激励计划"）首次授予登记工作，现将有关事项公告如 下： 一、本激励计划已履行的决策程序和信息披露情况 1．2025年8月7日，公司召开第七届董事会第三次会议，审议通过了《关于〈北京中科金财科技股份有 限公司2025年限制性股票激励计划（草案）〉及其摘要的议案》、《关于〈北 ...

格隆汇9月21日丨金时科技(002951.SZ)公布2025年限制性股票激励计划，本激励计划拟授予激励对象的 限制性股票数量为387.22万股，约占本激励计划草案公布日公司股本总额的0.96%。本次授予为一次性 授予，无预留权益。截至本激励计划草案公布日，公司全部在有效期内的股权激励计划所涉及的标的股 票总数累计未超过公司股本总额的10%。本激励计划中任何一名激励对象通过全部在有效期内的股权激 励计划获授的公司股票数量累计未超过公司股本总额的1%。 ...

Summary of Key Points Core Viewpoint - Xianheng International (605056) has announced a restricted stock incentive plan for 2025, aiming to enhance employee motivation and align their interests with the company's performance [1] Company Announcement Summary - Xianheng International plans to grant 6 million shares of restricted stock to 174 incentive recipients, representing 1.46% of the company's total share capital [1] - The stock will be sourced from shares repurchased from the secondary market, with a grant price set at 7.29 yuan per share [1] - The incentive recipients include senior management and core personnel, excluding independent directors and supervisors [1] - The plan has a maximum validity period of 48 months, with lock-up periods of 12, 24, and 36 months, and the release of restrictions tied to performance metrics [1] - Performance targets for the release of restrictions are based on revenue and net profit from 2025 to 2027, with individual performance evaluations categorized as excellent, qualified, or unqualified, corresponding to release ratios of 100%, 80%, and 0% respectively [1]

Core Viewpoint - Shanghai Huid Technology Co., Ltd. has completed the registration of the reserved portion of its 2024 restricted stock incentive plan, granting 621,750 shares at a price of 6.90 yuan per share to 30 eligible participants, following an adjustment from the previous price of 7.27 yuan per share [2][22]. Group 1: Restricted Stock Grant Details - The reserved portion of restricted stock was granted on August 29, 2025, with a total of 621,750 shares allocated [3][5]. - The adjustment of the grant price from 7.27 yuan to 6.90 yuan was approved by the board due to the completion of the 2024 annual profit distribution [2][22]. - The total number of shares after the grant increased from 141,132,667 to 141,754,417 [17][22]. Group 2: Performance Conditions and Vesting - The vesting of the restricted stock is contingent upon meeting performance targets for the fiscal years 2024, 2025, and 2026, with annual assessments [9][12]. - If the company fails to meet the performance targets, the corresponding restricted stock will not be released and will be subject to buyback at the grant price plus interest [12][14]. Group 3: Financial Impact and Use of Funds - The funds raised from the restricted stock grant will be used to supplement the company's working capital [18]. - The stock option plan is expected to have a minor impact on the company's net profit due to the amortization of stock payment expenses, but it is anticipated to enhance overall company performance [19][20].

Group 1 - The core point of the article is the announcement of Bluefeng Biochemical's restricted stock incentive plan, which involves granting 20.03 million shares to 72 individuals at a price of 2.64 yuan per share, representing 5.63% of the company's total share capital before the announcement [1] - The effective period of the restricted stock is up to 36 months from the completion of the registration of the stock grant [1] - As of the first half of 2025, Bluefeng Biochemical's revenue composition is 77.39% from photovoltaic products and 22.61% from pesticides [1] Group 2 - The current market capitalization of Bluefeng Biochemical is 1.9 billion yuan [1]